Apexigen, Inc.

Apexigen, Inc. (Nasdaq: APGN) is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for oncology indications. The company entered the public markets through a SPAC merger with Brookline Capital Acquisition Corp., a blank-check vehicle sponsored by Brookline Capital Markets that completed its IPO in 2021. The de-SPAC transaction closed in 2022, listing Apexigen on Nasdaq under the ticker APGN. On August 22, 2023, Apexigen filed an 8-K with the Securities and Exchange Commission disclosing a material corporate event. Sign up for full data and filing alerts on APGN and the broader de-SPAC universe at SpacDesk.